AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Spyre Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG0067L94C1
90.33▼ 2.00 (-2.17%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
92.33
Day's Range
88.69 – 91.90
52-Week Range
21.15 – 110.18
Volume
500.7K
Avg Volume
1.4M
Share Statistics
Shares Outstanding
Employees
102
Exchange
XNAS
Listed
2016-04-07
Share count as of July 28, 2026

Spyre Therapeutics, Inc. Common Stock (SYRE) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Spyre Therapeutics, Inc. Common Stock (SYRE)
What is Spyre Therapeutics, Inc. Common Stock's Market Cap?
Spyre Therapeutics, Inc. Common Stock's Market Cap is $8.0B, based on as-reported figures from SEC (XBRL) filings.
What is Spyre Therapeutics, Inc. Common Stock's Revenue (TTM)?
Spyre Therapeutics, Inc. Common Stock's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Spyre Therapeutics, Inc. Common Stock's Net Income (TTM)?
Spyre Therapeutics, Inc. Common Stock's Net Income (TTM) is -$178.9M, based on as-reported figures from SEC (XBRL) filings.
What is Spyre Therapeutics, Inc. Common Stock's EBITDA?
Spyre Therapeutics, Inc. Common Stock's EBITDA is -$201.3M, based on as-reported figures from SEC (XBRL) filings.
What is Spyre Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Spyre Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -2.03, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · SYREAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
General and administrative
Gain on sale of in-process research and development asset
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Other (expense) income, net
Total other income (expense)
Loss before income tax expense
Income tax benefit
Net loss
Net loss per share, basic (in dollars per share)————
Net loss per share, diluted (in dollars per share)———